Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lucid DiagnosticsLUCD -3.82%16 Operating Cash Flow per Share is $-0.35 as of Jun. 2026. GuruFocus rates LUCD with a GF Score™ of 16/100 and a GF Value™ of $0.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 651 Medical Devices & Instruments companies, Lucid Diagnostics ranks better than 58.06% on this metric.
Lucid Diagnostics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.06.
Lucid Diagnostics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.35.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.80% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Lucid Diagnostics's Operating Cash Flow per Share or its related term are showing as below:
LUCD'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -134.1 Med: -35.1 Max: 17.8
Current: 17.8
During the past 7 years, Lucid Diagnostics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 17.80% per year. The lowest was -134.10% per year. And the median was -35.10% per year.
LUCD's 3-Year OCF Growth Rate is ranked better than 58.06% of 651
companies
in the Medical Devices & Instruments industry
Industry Median: 12.1
vs LUCD: 17.80
Lucid Diagnostics Operating Cash Flow per Share Related Terms
Lucid Diagnostics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics Operating Cash Flow per Share Chart
LUCD vs QSI, STIM, INGN: Operating Cash Flow per Share Comparison
For the Medical Devices subindustry, Lucid Diagnostics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.35 mean?
Lucid Diagnostics (LUCD) has a Operating Cash Flow per Share of $-0.35 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Lucid Diagnostics and its competitors. According to the industry distribution chart, Lucid Diagnostics ranks #273 out of 651 companies in the Medical Devices & Instruments industry, placing it in the top 41.9%.
Is Lucid Diagnostics' Operating Cash Flow per Share too high?
Lucid Diagnostics' current Operating Cash Flow per Share is $-0.35. Based on the distribution chart, Lucid Diagnostics ranks #273 out of 651 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Lucid Diagnostics has a GF Score™ of 16/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Operating Cash Flow per Share compare to QSI and STIM?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #273 out of 651 companies for Operating Cash Flow per Share. This puts Lucid Diagnostics in the upper half of its industry. The industry median Operating Cash Flow per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.10, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Operating Cash Flow per Share is $-0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.73, compared to a current price of $0.95 — trading 30.2% above its estimated fair value. The current Operating Cash Flow per Share is $-0.35. Lucid Diagnostics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Operating Cash Flow per Share is $-0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $0.95 is trading 30.2% above its estimated GF Value™ of $0.73.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
Operating Cash Flow per Share: $-0.35
GF Value™: $0.73 vs. price of $0.95 (30.2% above fair value)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
16GF Score
Get the complete analysis for LUCD
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
